Vaxart (NasdaqCM:VXRT) FY Conference Transcript

Vaxart FY Conference Summary Company Overview - Company: Vaxart (NasdaqCM: VXRT) - Industry: Biopharmaceuticals, specifically vaccine development Core Points and Arguments 1. Vaccine Platform: Vaxart is developing an oral pill vaccine platform that aims to provide both systemic and mucosal immunity, presenting a potential alternative to traditional injectable vaccines [2][3][4] 2. Thermal Stability: The oral pill vaccine is thermally stable, facilitating easier administration and distribution, with all manufacturing conducted in the United States [3][4][21] 3. Current Vaccine Candidates: Vaxart is working on vaccines for norovirus, COVID-19, flu, and potentially human papillomavirus (HPV) in the future [2][5][21] 4. Norovirus Vaccine: - The economic burden of norovirus exceeds $10 billion annually, with no approved vaccines currently available [6] - Vaxart's bivalent vaccine targets dominant strains GII.1 and GII.4, showing promise in reducing infection rates [7][9] - Phase 2 challenge study results indicated a 30% relative reduction in infections compared to placebo [10] - A next-generation vaccine candidate is set to progress to phase 2B trials, with discussions ongoing for potential partnerships and funding [12][18] 5. COVID-19 Vaccine: - A head-to-head study against an approved mRNA vaccine is ongoing, with 5,000 subjects enrolled in a BARDA-funded phase 2B clinical trial [12][13] - The trial aims to establish safety and tolerability, with a 12-month efficacy endpoint expected in the second half of 2026 [14][19] 6. Flu Vaccine: - Previous phase 2 challenge studies showed Vaxart's oral vaccine provided a 49% reduction in influenza infection compared to placebo, outperforming a leading injectable vaccine [17] - The company is also exploring a vaccine for avian flu (H5N1), with promising preclinical animal data [16][18] Additional Important Content 1. Management Team: Vaxart's leadership includes experts with extensive experience in vaccine development and manufacturing, emphasizing the company's strong foundation [20] 2. Market Opportunity: Vaxart positions itself as a pioneer in the vaccine space, particularly in addressing unmet medical needs with its innovative oral vaccine platform [18][21] 3. Funding and Milestones: The company is focused on securing funding to advance its vaccine candidates through clinical trials, with a cash runway extending to the first quarter of the following year [18][19] This summary encapsulates the key insights from Vaxart's FY conference, highlighting the company's innovative approach to vaccine development and its strategic focus on addressing significant health challenges.